Complement System

The complement system is a sophisticated part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells, promotes inflammation, and attacks the pathogen's cell membrane. This system is named for its capacity to "complement" the killing of pathogens by antibodies.

Comprising over 30 small proteins produced by the liver, the complement system circulates in the blood serum and within tissues throughout the body. These proteins are normally inactive but become sequentially activated in response to a pathogen. Activation can occur via three pathways: the classical pathway, which is triggered by antibodies bound to a pathogen; the lectin pathway, which is activated by mannose-binding lectin attaching to the pathogen surface; and the alternative pathway, which can be initiated directly by pathogen surfaces.

Each pathway leads to the cleavage of the protein C3, generating C3a and C3b fragments. C3b binds to the pathogen surface and can lead to direct opsonization—tagging the pathogen for destruction by phagocytes. C3a, along with other small fragments released during complement activation, acts as a chemoattractant to recruit immune cells to the site of infection and promote inflammation.

The final common step of the complement activation pathways is the assembly of the membrane attack complex (MAC). This complex forms a pore in the membrane of the target cell, leading to cell lysis and death. The MAC is particularly effective against gram-negative bacteria.

Regulation of the complement system is crucial, as overactivation can damage host cells. Regulators are present in blood plasma and on cell surfaces, ensuring the system is directed only at pathogens or damaged cells.

The complement system plays a crucial role not only in innate immunity but also as a bridge to adaptive immunity. It assists in clearing immune complexes and apoptotic cells, and in enhancing the humoral response and immune memory.

Understanding and manipulating the complement system has therapeutic potential for numerous diseases, including those that involve excessive or inappropriate activation of the complement pathways.

Items 26-50 of 81

  • PIC1 PA
    Cat. No.
    A24467

    PIC1 PA

    PIC1 PA is a 15-amino-acid peptide and a potent analog of PIC1 that inhibits classical pathway–mediated complement activation. It functions by disrupting the interaction between C1s-C1r-C1r-C1s/MASPs and the collagen-like region (CLR) of C1q or MBL. PIC1 PA specifically binds to the CLR of C1q, with a mean equilibrium dissociation constant (K\_D) of 33.3 nM for purified C1q.

    1 mg
    $54.00
    5 mg
    $162.00
    All 4 sizes
  • Campneoside II
    Cat. No.
    A24468

    Campneoside II

    Campneoside II is a natural compound isolated from the wood of *Paulownia tomentosa* var. *tomentosa*. It exhibits potent anti-complement activity.

    1 mg
    $180.00
    5 mg
    $540.00
    All 4 sizes
  • CP-447697
    Cat. No.
    A24469

    CP-447697

    CP-447697 is a lipophilic C5a receptor antagonist with an IC₅₀ value of 31 nM. It is suitable for research related to inflammation and complement system modulation.

    5 mg
    $72.00
    10 mg
    $124.00
    All 4 sizes
  • Zoracopan
    Cat. No.
    A24470

    Zoracopan

    Zoracopan is a selective inhibitor of complement factor D (CFD). Upon systemic administration (oral or intravenous), it preferentially accumulates in ocular tissues and is released in a sustained manner, primarily targeting the choroid–retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB).

    1 mg
    $270.00
    5 mg
    $810.00
    All 4 sizes
  • LyP-1
    Cat. No.
    A24471

    LyP-1

    LyP-1 is a cyclic 9-amino-acid tumor-homing peptide that selectively binds to p32 receptors, which are overexpressed on various tumor-associated cells.

    5 mg
    $90.00
    10 mg
    $155.00
    All 4 sizes
  • BR103
    Cat. No.
    A24472

    BR103

    BR103 is a C3a receptor (C3aR)-specific small molecule ligand. It is useful for measuring ligand affinity to G protein-coupled receptors (GPCRs) through saturation and competitive binding assays.

    5 mg
    $225.00
    10 mg
    $388.00
    All 4 sizes
  • Pelecopan
    Cat. No.
    A24473

    Pelecopan (BCX9930)

    Synonyms: BCX9930

    Pelecopan (BCX9930) is a potent, selective, and orally active inhibitor of complement factor D, with an IC₅₀ value of 14.3 nM. It targets factor D to prevent both intravascular and extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and is also applicable to other diseases mediated by the alternative complement pathway.

    5 mg
    $315.00
    10 mg
    $543.00
    All 4 sizes
  • NDT 9513727
    Cat. No.
    A24474

    NDT 9513727

    NDT 9513727 is a potent, selective, orally active, and competitive inverse agonist of the human C5a receptor (C5aR), with an IC₅₀ of 11.6 nM. It is suitable for research in human inflammatory diseases.

    5 mg
    $81.00
    10 mg
    $140.00
    All 4 sizes
  • BM213
    Cat. No.
    A24475

    BM213

    BM213 is a potent and selective agonist of C5aR1 that demonstrates antitumor activity in a mouse model of mammary carcinoma.

    5 mg
    $90.00
    10 mg
    $155.00
    All 4 sizes
  • Cemdisiran
    Cat. No.
    A24476

    Cemdisiran (ALN-CC5)

    Synonyms: ALN-CC5

    Cemdisiran is an N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) designed to suppress hepatic production of complement component 5 (C5). It is used in research focused on complement-mediated diseases.

    1 mg
    $63.00
    5 mg
    $189.00
    All 4 sizes
  • C3a receptor agonist 1
    Cat. No.
    A24478

    C3a receptor agonist 1

    C3a Receptor Agonist 1 (a benzeneacetamide derivative) is a potent agonist of the C3a receptor. It holds potential for research in acute inflammation and complement system–mediated responses.

    1 mg
    $81.00
    5 mg
    $243.00
    All 4 sizes
  • W-54011
    Cat. No.
    A24479

    W-54011

    W-54011 is a potent, orally active, non-peptide antagonist of the C5a receptor. It inhibits the binding of \[¹²⁵I]-labeled C5a to human neutrophils with a Kᵢ of 2.2 nM. W-54011 also suppresses C5a-induced intracellular Ca²⁺ mobilization, chemotaxis, and reactive oxygen species (ROS) generation in human neutrophils, with IC₅₀ values of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.

    1 mg
    $45.00
    5 mg
    $135.00
    All 4 sizes
  • Vemircopan
    Cat. No.
    A24480

    Vemircopan (ALXN2050)

    Synonyms: ACH 0145228; ACH-5228; ALXN2050

    Vemircopan (ALXN2050) is an orally active inhibitor of complement factor D (FD). It is being investigated for the treatment of complement-mediated diseases, including myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria (PNH).

    1 mg
    $270.00
    5 mg
    $810.00
    All 4 sizes
  • Lipoteichoic acid
    Cat. No.
    A24481

    Lipoteichoic acid

    Lipoteichoic acid is an orally active compound with anti-inflammatory and antitumor properties. It is a key immune molecule found in Gram-positive bacteria that activates the complement system by upregulating C3 and inhibiting CD55. Lipoteichoic acid modulates macrophage autophagy via the PI3K/Akt/mTOR pathway, induces lung injury in mouse models, and inhibits melanin production.

    1 mg
    $162.00
    5 mg
    $486.00
    All 4 sizes
  • Perforin-IN-2
    Cat. No.
    A24482

    Perforin-IN-2

    Perforin-IN-2 (Compound 1) is a perforin inhibitor that blocks perforin-mediated cell lysis. It has potential to reduce graft rejection in the context of allogeneic bone marrow or stem cell transplantation.

    5 mg
    $180.00
    10 mg
    $310.00
    All 4 sizes
  • EG01377 dihydrochloride
    Cat. No.
    A24483

    EG01377 dihydrochloride

    EG01377 dihydrochloride is a potent, bioavailable, and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM and IC₅₀ values of 609 nM for both NRP1-a1 and NRP1-b1 domains. It exhibits antiangiogenic, antimigratory, and antitumor activities.

    1 mg
    $108.00
    5 mg
    $324.00
    All 4 sizes
  • JPE-1375
    Cat. No.
    A24484

    JPE-1375

    JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist that effectively inhibits polymorphonuclear leukocyte mobilization with an EC₅₀ of 6.9 µM and reduces TNF levels with an EC₅₀ of 4.5 µM in mice. It is suitable for research in autoimmune and inflammatory diseases.

    5 mg
    $108.00
    10 mg
    $186.00
    All 4 sizes
  • Dextran sulfate sodium salt (MW 5000)
    Cat. No.
    A30006

    Dextran sulfate sodium salt (MW 5000)

    Synonyms: DSS (MW 5000); DXS (MW 5000)

    Dextran sulfate sodium salt (DSS, MW 5000) primarily functions as a complement inhibitor, derived from a polymer of dehydrated glucose. This compound exhibits significant biological activities, including anticoagulation, antiviral properties, and anti-lipemic effects. Its mechanisms involve blocking HIV-1 adsorption to host cells, preventing natural killer (NK) cell-mediated cytotoxicity, and inhibiting instant blood-mediated inflammatory reactions (IBMIR). Dextran sulfate sodium salt (MW 5000) is valuable in research related to immunology, virology, and cardiovascular studies.

    5 g
    $25.00
    10 g
    $30.00
    All 4 sizes
  • Iptacopan TFA
    Cat. No.
    A35179

    Iptacopan TFA

    Synonyms: LNP023 TFA

    Iptacopan TFA is a selective inhibitor of Factor B, demonstrating an IC50 value of 10 nM and a KD of 7.9 nM. This compound modulates the complement cascade, effectively preventing hemolysis of red blood cells in paroxysmal nocturnal hemoglobinuria (PNH) and protecting renal cells in primary immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G). Iptacopan TFA is applicable for research into complement-mediated diseases, providing insights into therapeutic strategies for conditions associated with dysregulated complement activity.

    Out of stock

    All 3 sizes
  • Agazisiran
    Cat. No.
    A35180

    Agazisiran

    Agazisiran is a small interfering RNA (siRNA) that targets and reduces the synthesis of complement factor B, a key component in the alternative complement pathway. By modulating complement activation, Agazisiran has potential applications in research focused on autoimmune diseases, inflammatory conditions, and other disorders where complement dysregulation plays a critical role.

    Out of stock

    All 3 sizes
  • Iptacopan hydrochloride
    Cat. No.
    A35182

    Iptacopan hydrochloride

    Synonyms: LNP023 hydrochloride

    Iptacopan hydrochloride is a highly selective inhibitor of Factor B, exhibiting an IC50 of 10 nM and a KD of 7.9 nM. This compound disrupts the complement cascade, thereby preventing hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and protecting renal cells in primary immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G). Iptacopan hydrochloride is valuable for research on complement-mediated diseases, facilitating the exploration of therapeutic strategies in these conditions.

    1 mg
    $40.00
    2 mg
    $60.00
    All 8 sizes
  • C5a Receptor agonist, W5Cha
    Cat. No.
    A35186

    C5a Receptor agonist, W5Cha

    C5a Receptor agonist, W5Cha, is a selective agonist of the complement C5a receptor (C5aR), exhibiting an EC50 of 0.2 μM. This hexapeptide is derived from the C-terminus of C5a and features specific amino acid modifications that enhance its bioactivity. W5Cha effectively activates the C5aR by interacting with the Arg-206 site, making it a valuable tool for studying C5aR-mediated signaling pathways and related biological processes in inflammatory responses.

    5 mg
    $80.00
    10 mg
    $125.00
    All 2 sizes
  • Sefaxersen sodium
    Cat. No.
    A35187

    Sefaxersen sodium

    Synonyms: IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium

    Sefaxersen sodium is a specific antisense oligonucleotide (ASO) that targets complement factor B (CFB). It effectively reduces circulating levels of CFB, making it a valuable tool for research into geographic atrophy (GA). This compound facilitates the exploration of therapeutic strategies aimed at modulating the complement pathway in ocular diseases.

    1 mg
    $225.00
    5 mg
    $550.00
    All 3 sizes
  • Factor D inhibitor 6
    Cat. No.
    A35189

    Factor D inhibitor 6

    Factor D Inhibitor 6 is a selective inhibitor of Factor D, exhibiting a potent inhibitory activity with an IC50 of 30 nM and a Kd of 6 nM. It demonstrates high specificity, being inactive against Factor B and not affecting classical or lectin complement pathway activation, as well as a range of receptors, ion channels, kinases, and proteases. This compound is useful in research involving the complement system and its associated pathways, providing significant potential for therapeutic application in diseases influenced by aberrant complement activation.

    1 mg
    $120.00
    5 mg
    $295.00
    All 6 sizes
  • C1s-IN-1 trihydrochloride
    Cat. No.
    A35191

    C1s-IN-1 trihydrochloride

    C1s-IN-1 trihydrochloride is a selective inhibitor of the C1s protease with a Ki of 5.8 μM. It effectively inhibits the cleavage of C2 by C1s with an IC50 of 85 μM and disrupts the activation of the classical pathway at an IC50 of 22 μM. Additionally, this compound acts as a competitive inhibitor for thrombin with a Ki of 51.2 μM, making it a valuable tool for research into complement system regulation and thrombin-related pathways.

    25 mg
    $60.00
    50 mg
    $95.00
    All 2 sizes

Items 26-50 of 81

Added to your cart

View Cart Checkout

    Loading...